【私募调研记录】鼎萨投资调研普门科技

Group 1 - The core viewpoint of the news highlights that DingSa Investment has conducted research on a listed company, focusing on its recent product developments and market strategies [1] - Pumen Technology has received CE certification for its fully automated chemiluminescence immunoassay analyzers eCL8600 and eCL8800, which are now available in international markets, enhancing the company's competitiveness in the global in vitro diagnostics sector [1] - The mid-speed luminescence products are designed to meet the needs of secondary hospitals in China, aiming to serve the basic healthcare market [1] Group 2 - In June, Pumen Technology's carbon dioxide laser treatment machine obtained domestic Class III medical device registration, indicating its capability to treat various skin conditions and its unique position in the aesthetic medical device market [1] - The company plans to continue investing in research and development to expand its portfolio of optical aesthetic medical products, aligning with consumer demands [1] - DingSa Investment, established in March 2012, has a strong track record in asset management and has received multiple awards for its performance in the private equity sector [2]